Vanguard Capital Management
BIVI icon

Vanguard Capital Management’s BioVie BIVI Stock Holding History

Vanguard Capital Management’s Portfolio BIVI Stock Details BIVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Sell
70,906
-13,161
-16% -$20.7K ﹤0.01% 3848
2026
Q1 		$118K Buy
+84,067
New +$108K ﹤0.01% 3848

Other funds holding BIVI

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.56B AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Vanguard Capital Management's BIVI Position: Q2 2026 in Review

Vanguard Capital Management reduced its BioVie (BIVI) stake by 16% in Q2 2026, selling an estimated $20.7K and leaving 70,906 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #3848.

Vanguard Capital Management first reported a position in BIVI in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold BIVI as of Q2 2026.

  • Vanguard Capital Management held 70,906 shares of BioVie worth $138K as of Q2 2026.
  • Vanguard Capital Management sold 13,161 BioVie shares in Q2 2026, an estimated $20.7K.
  • BioVie made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3848 holding.
  • Vanguard Capital Management first reported a position in BioVie in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held BioVie as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.